Liver/Biliary Disorders News

The AGA published clinical practice guidelines in Gastroenterology for the management of coagulation disorders among patients with cirrhosis.

Healio Gastroenterology presents the following report on the top 10 peer-tested stories from the ACG Annual Scientific Meeting 2021.

The FDA granted fast track designation to LPCN 1144 as a treatment for non-cirrhotic nonalcoholic steatohepatitis, according to a release from Lipocine.

The CDC’s Advisory Committee on Immunization Practices voted unanimously, 15-0, on Wednesday to recommend hepatitis B vaccination for all adults aged 19 to 59 years.

LAS VEGAS — In this video exclusive, Kevin Moore, MD, discussed a study assessing real-world outcomes in patients with esophageal variceal hemorrhage and liver cirrhosis treated with terlipressin.

LAS VEGAS – In this video exclusive, Nancy S. Reau, MD, FAASLD, AGAF, discussed the Liver Health Annual Trends Report, which was launched during a panel discussion hosted by Salix Pharmaceuticals at the ACG Annual Scientific Meeting.

LAS VEGAS – Pharmacological treatments of alcohol use disorder have been found to improve mortality outcomes for patients with alcohol-associated liver disease, according to a presenter at the ACG Annual Scientific Meeting.

LAS VEGAS – A trained convolutional neural network detected key cholangioscopy image features suggestive of malignancy supporting intra-procedural decision making, according to a presentation at the ACG Annual Scientific Meeting.

LAS VEGAS — Fecal microbiota transplant capsules may improve cognition in patients with hepatic encephalopathy; however, results may vary by donor and recipient factors, according to a presentation at the ACG Annual Scientific Meeting. “FMT is likely safe with rigorous screening protocol, though some patient subgroups with very advanced cirrhosis and decompensated disease potentially warrant exclusion of this treatment,” Patricia P. Bloom, MD, transplant hepatologist from the University of Michigan, said during the presentation. “It is possible reversing rifaximin (Xifaxan, Salix Pharmaceuticals) resistance is another mechanism by which FMT is effective in this condition.”

LAS VEGAS — No safety and efficacy concerns for COVID-19 messenger RNA vaccines were noted among patients with cirrhosis compared with the general population, according to a presentation at the ACG Annual Scientific Meeting.